A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding

被引:63
作者
McClain, Monica R. [1 ]
Palomaki, Glenn E. [1 ]
Piper, Margaret [2 ]
Haddow, James E. [1 ]
机构
[1] Brown Univ, Women & Infants Hosp, Warren Alpert Sch Med, Dept Pathol & Lab Med, Providence, RI USA
[2] Blue Cross & Blue Shield Technol Evaluat Ctr, Chicago, IL USA
关键词
evidence review; warfarin; CYP2C9; VKORC1; severe bleeding;
D O I
10.1097/GIM.0b013e31815bf924
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Summarize evidence regarding genetic testing in adults to inform warfarin dosing to reduce adverse drug events such as serious bleeding. Methods: Review published (and selected gray) literature using the Rapid-ACCE structure that addresses analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications. Results: Preliminary data suggest overall analytic sensitivity and specificity will be 98% or higher for CYP2C9 genotyping, but strength of evidence for analytic validity is low, especially for VKORC1 testing. Strength of evidence is high for the clinical validity of both genes in predicting stable warfarin dose, an intermediate outcome, but is low for the association between CYP2C9 testing and severe bleeding events (clinical sensitivity 46% (95% CI 32-60%); specificity 69% (95% CI 62-75%) and absent for bleeding events associated with VKORC1 testing. No data are available to document clinical utility of genotyping before warfarin dosing. Conclusions: The most important gaps identified are: which variants should be included in a testing panel, lack of data from external proficiency testing, lack of validated dosing algorithm incorporating genetic and nongenetic factors, evidence of clinical utility, reliable economic analyses, and methods to address several ethical, legal, and social implications issues.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 64 条
[1]  
[Anonymous], 0623 AEI BROOK JOINT
[2]   Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements [J].
Aquilante, CL ;
Langaee, TY ;
Lopez, LM ;
Yarandi, HN ;
Tromberg, JS ;
Mohuczy, D ;
Gaston, KL ;
Waddell, CD ;
Chirico, MJ ;
Johnson, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :291-302
[3]   Comparison of cytochrome P4502C9 genotyping methods and implications for the clinical laboratory [J].
Aquilante, CL ;
Lobmeyer, MT ;
Langaee, TY ;
Johnson, JA .
PHARMACOTHERAPY, 2004, 24 (06) :720-726
[4]   Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population [J].
Burian, M ;
Grösch, S ;
Tegeder, I ;
Geisslinger, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :518-521
[5]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[6]   Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery [J].
Enyart, JJ ;
Jones, RJ .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (06) :1002-1007
[7]   Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing™ technology [J].
Eriksson, S ;
Berg, LM ;
Wadelius, M ;
Alderborn, A .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2002, 1 (01) :49-59
[8]   Prevention of venous thromboembolic disease following primary total knee arthroplasty - A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin [J].
Fitzgerald, RH ;
Spiro, TE ;
Trowbridge, AA ;
Gardiner, GA ;
Whitsett, TL ;
O'Connell, MB ;
Ohar, JA ;
Young, TR .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2001, 83A (06) :900-906
[9]   Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin [J].
Flockhart, David A. ;
O'Kane, Dennis ;
Williams, Marc S. ;
Watson, Michael S. ;
Flockhart, David A. ;
Gage, Brian ;
Gandolfi, Roy ;
King, Richard ;
Lyon, Elaine ;
Nussbaum, Robert ;
O'Kane, Dennis ;
Schulman, Kevin ;
Veenstra, David ;
Williams, Marc S. ;
Watson, Michael S. .
GENETICS IN MEDICINE, 2008, 10 (02) :139-150
[10]   Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement [J].
Francis, CW ;
Berkowitz, SD ;
Comp, PC ;
Lieberman, JR ;
Ginsberg, JS ;
Paiement, G ;
Peters, GR ;
Roth, AW ;
McElhattan, J ;
Colwell, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (18) :1703-1712